Does anti-high mobility group box 1 monoclonal antibody improve ischemia/reperfusion injury and mode of liver regeneration after partial hepatectomy?
Anti-HMGB1 mAb ameliorated IRI and improved the mode of liver regeneration after IRI followed by 70% hepatectomy in rats.
Pretransplantation therapy with TKI2 in CP CML is safe and reasonable. In BC, the optimal approach before HCT is to reduce the leukemic burden and achieve subsequent CP.